| Too few, too weak: conflict of interest policies at Canadian medical schools A Shnier, J Lexchin, B Mintzes, A Jutel, K Holloway PloS one 8 (7), e68633, 2013 | 57 | 2013 |
| Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine Q Grundy, C Mayes, K Holloway, S Mazzarello, BD Thombs, L Bero Journal of clinical epidemiology 120, 1-7, 2020 | 44 | 2020 |
| Blood donation and the global COVID‐19 pandemic: areas for social science research J Haw, K Holloway, BM Masser, EM Merz, R Thorpe Vox sanguinis 116 (4), 363, 2021 | 37 | 2021 |
| Normalizing complaint: Scientists and the challenge of commercialization KJ Holloway Science, Technology, & Human Values 40 (5), 744-765, 2015 | 37 | 2015 |
| Half a century of Wilson & Jungner: reflections on the governance of population screening S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ... Wellcome Open Research 5, 2020 | 29 | 2020 |
| A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research KHM Herder Journal of Responsible Innovation, 2019 | 24 | 2019 |
| Uneasy subjects: Medical students' conflicts over the pharmaceutical industry K Holloway Social Science & Medicine 114, 113-120, 2014 | 22 | 2014 |
| ‘Something there is that doesn’t love a wall’: Histories of the placental barrier A Martin, K Holloway Studies in History and Philosophy of Science Part C: Studies in History and …, 2014 | 21 | 2014 |
| Health Canada needs to act on laboratory-developed diagnostics K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth CMAJ 191 (39), E1067-E1069, 2019 | 17 | 2019 |
| Industry, experts and the role of the ‘invisible college’in the dissemination of non-invasive prenatal testing in the US K Holloway, FA Miller, N Simms Social science & medicine 270, 113635, 2021 | 14 | 2021 |
| Dangerous diagnostics? Regulatory reform in the genomic era K Holloway, FA Miller, A Gutierrez, S Hogarth BMJ 364, 2019 | 9 | 2019 |
| Blood collection agency messaging to donors and the public in Canada and Australia during the early days of COVID-19 J Haw, R Thorpe, K Holloway Frontiers in Communication 6, 777829, 2022 | 8 | 2022 |
| Understanding the experiences of plasma donors in Canada's new source plasma collection centres during COVID‐19: A qualitative study K Holloway Vox Sanguinis, 2022 | 7 | 2022 |
| The market in noninvasive prenatal tests and the message to consumers: exploring responsibility K Holloway, N Simms, RZ Hayeems, FA Miller Hastings Center Report 52 (2), 49-57, 2022 | 7 | 2022 |
| The Consultant's intermediary role in the regulation of molecular diagnostics in the US K Holloway, FA Miller Social science & medicine 304, 112929, 2022 | 6 | 2022 |
| Teaching conflict: Professionalism and medical education KJ Holloway Journal of bioethical inquiry 12, 675-685, 2015 | 6 | 2015 |
| What influences decisions to donate plasma? A rapid review of the literature M Berger, A Easterbrook, K Holloway, D Devine, N Bansback Vox Sanguinis 118 (10), 817-824, 2023 | 3 | 2023 |
| ‘A Most Equitable Drug’: How the Clinical Studies of Convalescent Plasma as a Treatment for SARS-CoV-2 Might Usefully Inform Post-Pandemic Public Sector Approaches to Drug … Q Grundy, C Campbell, R Ali, M Herder, K Holloway The Journal of Law, Medicine & Ethics, 2023 | 2 | 2023 |
| How do we forecast tomorrow’s transfusion? Applying social science approaches to meet tomorrow’s transfusion needs: Blood donors and donation J Haw, K Holloway, M Goldman Transfusion Clinique et Biologique 30 (1), 47-51, 2023 | 1 | 2023 |
| A Troubled Solution: Medical Student Struggles with Evidence and Industry Bias KJ Holloway Science and engineering ethics 21, 1673-1689, 2015 | 1 | 2015 |
